Journal of Clinical Oncology, Vol 6, 270-275, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors

DM Gershenson
Department of Gynecology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston 77030.

Forty patients who had been treated for malignant ovarian germ cell tumors completed a questionnaire designed to evaluate their menstrual and reproductive function. All patients met the following eligibility criteria: (1) successful treatment with combination chemotherapy, and (2) retention of a normal contralateral ovary and uterus. Median age at diagnosis was 15 years (range, 6 to 29), and median age at the time of interview was 25.5 years (range, 14 to 40). Patients had received a variety of chemotherapeutic regimens, the most common of which was a combination of vincristine, dactinomycin, and cyclophosphamide (N = 28). Since discontinuation of chemotherapy, one patient remains premenarchal, and 27 patients have maintained regular menses. The other 12 patients have had menstrual difficulties, but in only three were the problems considered to be serious. Of the 16 patients who have attempted to become pregnant since completing chemotherapy, 11 have delivered 22 healthy infants, none of whom had major birth defects. Only one patient has had persistent problems with infertility. In summary, it appears that the majority of patients who receive combination chemotherapy for malignant ovarian germ cell tumors can anticipate normal menstrual function and a reasonable probability of having normal offspring.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. de La Motte Rouge, P. Pautier, P. Duvillard, A. Rey, P. Morice, C. Haie-Meder, P. Kerbrat, S. Culine, F. Troalen, and C. Lhomme Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor Ann. Onc., August 1, 2008; 19(8): 1435 - 1441. [Abstract] [Full Text] [PDF]

				D. M. Gershenson Management of Ovarian Germ Cell Tumors J. Clin. Oncol., July 10, 2007; 25(20): 2938 - 2943. [Abstract] [Full Text] [PDF]

				D. M. Gershenson, A. M. Miller, V. L. Champion, P. O. Monahan, Q. Zhao, D. Cella, and S. D. Williams Reproductive and Sexual Function After Platinum-Based Chemotherapy in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study J. Clin. Oncol., July 1, 2007; 25(19): 2792 - 2797. [Abstract] [Full Text] [PDF]

				Y. Kitajima, T. Endo, T. Hayashi, S. Ishioka, T. Baba, H. Honnma, and T. Saito A successful IVF-pregnancy in a patient who underwent conservative surgery followed by a regimen of cisplatin, vinblastine and peplomycin to treat an advanced ovarian mixed germ cell tumour: A Case Report Hum. Reprod., March 1, 2007; 22(3): 850 - 852. [Abstract] [Full Text] [PDF]

				B. Simon, S. J. Lee, A. H. Partridge, and C. D. Runowicz Preserving Fertility After Cancer CA Cancer J Clin, July 1, 2005; 55(4): 211 - 228. [Abstract] [Full Text] [PDF]

				D. M. Gershenson Fertility-Sparing Surgery for Malignancies in Women J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 43 - 47. [Abstract] [Full Text] [PDF]

				G. Zanetta, C. Bonazzi, M. G. Cantu, A. Locatelli, G. Bratina, and C. Mangioni Survival and Reproductive Function After Treatment of Malignant Germ Cell Ovarian Tumors J. Clin. Oncol., February 15, 2001; 19(4): 1015 - 1020. [Abstract] [Full Text] [PDF]

				M. Brewer, D. M. Gershenson, C. E. Herzog, M. F. Mitchell, E. G. Silva, and J. T. Wharton Outcome and Reproductive Function After Chemotherapy for Ovarian Dysgerminoma J. Clin. Oncol., September 1, 1999; 17(9): 2670 - 2670. [Abstract] [Full Text] [PDF]

				K. L. Lenz and A. W. Valley Review : Infertility after chemotherapy: A review of the risks and strategies for prevention Journal of Oncology Pharmacy Practice, January 1, 1996; 2(2): 75 - 100. [Abstract] [PDF]

				L. R. Ferguson Occupational health and staff monitoring: A genetic toxicologist's viewpoint Journal of Oncology Pharmacy Practice, January 1, 1995; 1(3): 49 - 54. [Abstract] [PDF]